These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3117472)

  • 1. Cost-effectiveness of therapeutic drug monitoring.
    Vozeh S
    Clin Pharmacokinet; 1987 Sep; 13(3):131-40. PubMed ID: 3117472
    [No Abstract]   [Full Text] [Related]  

  • 2. Statistical problems in monitoring adverse drug reactions.
    Moussa MA
    Methods Inf Med; 1978 Apr; 17(2):106-12. PubMed ID: 661604
    [No Abstract]   [Full Text] [Related]  

  • 3. Active Monitoring of Adverse Drug Reactions with Neural Network Technology.
    Wu T; Gao CC; Lin JS; Zha JL
    Chin Med J (Engl); 2017 Jun; 130(12):1498-1501. PubMed ID: 28584215
    [No Abstract]   [Full Text] [Related]  

  • 4. Statisical logic in the monitoring of reactions to therapeutic drugs.
    Finney DJ
    Methods Inf Med; 1971 Oct; 10(4):237-45. PubMed ID: 5124593
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse drug reactions: a pharmacist-based monitoring system.
    Gardner P; Watson LJ
    Clin Pharmacol Ther; 1970; 11(6):802-7. PubMed ID: 5481567
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost-effectiveness of therapeutic drug monitoring.
    Pippenger CE
    Ther Drug Monit; 1990 Sep; 12(5):418. PubMed ID: 2127323
    [No Abstract]   [Full Text] [Related]  

  • 7. Toward the operational identification of adverse drug reactions.
    Karch FE; Lasagna L
    Clin Pharmacol Ther; 1977 Mar; 21(3):247-54. PubMed ID: 837643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions to drugs.
    Kimbel KH
    Lancet; 1977 Feb; 1(8006):308. PubMed ID: 64832
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse drug reactions: reducing the burden of treatment.
    Jordan S
    Nurs Stand; 2007 May 2-8; 21(34):35-41. PubMed ID: 17518073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once is not enough.
    Gross F
    Eur J Clin Pharmacol; 1977; 11(5):323-4. PubMed ID: 880970
    [No Abstract]   [Full Text] [Related]  

  • 11. [Active prospective monitoring of pharmacotherapy safety in outpatients: practical value].
    Nazimkin KE; Kukes VG
    Antibiot Khimioter; 2008; 53(11-12):39-43. PubMed ID: 19441657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience in monitoring drug reactions in outpatients. The Kaiser-Permanente Drug Monitoring System.
    Friedman GD; Collen MF; Harris LE; Van Brunt EE; Davis LS
    JAMA; 1971 Aug; 217(5):567-72. PubMed ID: 5109088
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital information systems and the quality of therapeutics.
    Blaschke TF
    Methods Inf Med; 1990 Jul; 29(3):163-6. PubMed ID: 2215257
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.
    Alagoz O; Durham D; Kasirajan K
    Pharmacogenomics J; 2016 Apr; 16(2):129-36. PubMed ID: 25987241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causes of severe morbidity/mortality cases.
    de Julien LF
    CDA J; 1983 Feb; 11(2):45-8. PubMed ID: 6572112
    [No Abstract]   [Full Text] [Related]  

  • 17. Balancing costs, efficacy, and side effects.
    Avorn J
    Pharmacoeconomics; 1994; 6 Suppl 1():63-6. PubMed ID: 10172483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting.
    Dormann H; Muth-Selbach U; Krebs S; Criegee-Rieck M; Tegeder I; Schneider HT; Hahn EG; Levy M; Brune K; Geisslinger G
    Drug Saf; 2000 Feb; 22(2):161-8. PubMed ID: 10672897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cost-effectiveness analysis in the era of pharmacogenomics.
    Flowers CR; Veenstra D
    Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An economic evaluation of a laboratory monitoring program for renin-angiotensin system agents.
    Smith DH; Raebel MA; Chan KA; Johnson ES; Petrik AF; Weiss JR; Yang X; Feldstein A
    Med Decis Making; 2011; 31(2):315-24. PubMed ID: 21393563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.